{"id":38630,"date":"2023-06-19T10:31:52","date_gmt":"2023-06-19T08:31:52","guid":{"rendered":"https:\/\/kapitalpartner.dk\/?p=38630"},"modified":"2023-06-19T10:31:55","modified_gmt":"2023-06-19T08:31:55","slug":"danish-biotech-weekly-week-25","status":"publish","type":"post","link":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-25\/","title":{"rendered":"Danish Biotech Weekly &#8211; Week 25"},"content":{"rendered":"\n<p><em>Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc. <\/em><\/p>\n\n\n\n<p><strong>In the past week, several companies reported results from clinical trials including Ascendis Pharma, Expres2ion and IO Biotech. Further, Saniona continued to soar with a 40% increase making the total return year-to-date more than 250% &#8211; probably due to invetors&#8217; huge interst in new weight loss products.<\/strong><\/p>\n\n\n\n<p><strong>Only 4 of the 20 listed, Danish biotech companies published news the past week. 11 of the 20 companies had a positive development in their share price for the week and 8 companies have had a positive share price performance year to date. Saniona is now the best performing stock this year<\/strong>.<\/p>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button has-custom-width wp-block-button__width-100\"><a class=\"wp-block-button__link has-luminous-vivid-amber-background-color has-background\" href=\"https:\/\/kapitalpartner.us12.list-manage.com\/subscribe?u=b37c4695f194050744e659a1a&amp;id=4d3d9004dc\"><strong>Register for the Danish Biotech Weekly newsletter<\/strong><\/a><\/div>\n<\/div>\n\n\n\n<p><\/p>\n\n\n\n<p class=\"has-luminous-vivid-amber-color has-text-color has-medium-font-size\"><strong>Company news the past week<\/strong><\/p>\n\n\n\n<p><strong>Ascendis Pharma<\/strong><\/p>\n\n\n\n<p><em>One-Year Data from Phase 3 Trial of TransCon\u2122 PTH in Adults with Hypoparathyroidism Presented at ENDO 2023<\/em> (<a href=\"https:\/\/www.globenewswire.com\/news-release\/2023\/06\/17\/2690015\/0\/en\/One-Year-Data-from-Phase-3-Trial-of-TransCon-PTH-in-Adults-with-Hypoparathyroidism-Presented-at-ENDO-2023.html\">Link<\/a>)<\/p>\n\n\n\n<p><a href=\"https:\/\/kapitalpartner.dk\/biosergen\/\"><strong>Biosergen<\/strong><\/a><\/p>\n\n\n\n<p><em><em><em><em><em><em>No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n<p><strong>Cessatech<\/strong><\/p>\n\n\n\n<p><em><em><em><em><em><em><em><em>No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n<p><a href=\"https:\/\/kapitalpartner.dk\/investeringscase-cs-medica\/\"><strong>CS Medica<\/strong><\/a><\/p>\n\n\n\n<p><em><em><em><em><em>CS MEDICA A\/S Secures Future Compliance with New Medical Device Regulation through Signed Contract with Notify Body<\/em><\/em><\/em><\/em><\/em> (<a href=\"https:\/\/news.cision.com\/cs-medica-a-s\/r\/cs-medica-a-s-secures-future-compliance-with-new-medical-device-regulation-through-signed-contract-w%2Cc3787969\">Link<\/a>)<\/p>\n\n\n\n<p>CS MEDICA A\/S Secures Trademark Approval in Canada (<a href=\"https:\/\/news.cision.com\/cs-medica-a-s\/r\/cs-medica-a-s-secures-trademark-approval-in-canada%2Cc3788778\">Link<\/a>)<\/p>\n\n\n\n<p><a href=\"https:\/\/kapitalpartner.dk\/curasight\/\"><strong>Curasight<\/strong><\/a><\/p>\n\n\n\n<p><em><em><em><em><em><em><em><em><em><em><em><em><em>No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n<p><strong>Evaxion Biotech<\/strong><\/p>\n\n\n\n<p><em><em><em><em><em>No news the past week<\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n<p><strong>Expres2ion<\/strong><\/p>\n\n\n\n<p><em><em><em><em><em>12-month durability data announced for ABNCoV2 Phase II clinical trial<\/em><\/em><\/em><\/em><\/em> (<a href=\"https:\/\/news.cision.com\/expres2ion-biotechnologies\/r\/12-month-durability-data-announced-for-abncov2-phase-ii-clinical-trial%2Cc3788597\">Link<\/a>)<\/p>\n\n\n\n<p><strong>Fluoguide<\/strong><\/p>\n\n\n\n<p><em><em><em><em><em>No news the past week<\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n<p><strong>Genmab<\/strong><\/p>\n\n\n\n<p><em>No news the past week<\/em><\/p>\n\n\n\n<p><strong>Gubra<\/strong><\/p>\n\n\n\n<p><em>No news the past week<\/em><\/p>\n\n\n\n<p><strong>Initiator Pharma<\/strong><\/p>\n\n\n\n<p><em>No news the past week<\/em><\/p>\n\n\n\n<p><strong>IO Biotech<\/strong><\/p>\n\n\n\n<p><em>IO Biotech Announces Achievement of Significant Phase 3 Clinical Trial Recruitment Milestone<\/em> (<a href=\"https:\/\/iobiotech.com\/press-releases\/?workflow=ef6f963c-bfc3-4a26-baa3-d9b5fa0bded2\">Link<\/a>)<\/p>\n\n\n\n<p><strong>Pila Pharma<\/strong><\/p>\n\n\n\n<p><em>No news the past week<\/em><\/p>\n\n\n\n<p><strong>Saniona<\/strong><\/p>\n\n\n\n<p><em><em><em><em>No news the past week<\/em><\/em><\/em><\/em><\/p>\n\n\n\n<p><strong>Scandion Oncology<\/strong><\/p>\n\n\n\n<p><em><em><em><em>No news the past week<\/em><\/em><\/em><\/em><\/p>\n\n\n\n<p><strong>SynAct Pharma<\/strong><\/p>\n\n\n\n<p><em><em><em><em><em><em>No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n<p><strong>ViroGates<\/strong><\/p>\n\n\n\n<p><em><em><em><em><em><em><em><em><em>No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n<p><strong>Zealand Pharma<\/strong><\/p>\n\n\n\n<p><em><em><em><em><em><em><em><em><em>No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n<p><strong>Y-mAbs Therapeutics<\/strong><\/p>\n\n\n\n<p><em>The average 1-year price target among brokers that have issued a report on the stock in the last year is USD13.67.<\/em> The stock is currently trading at USD7.58.<\/p>\n\n\n\n<p><strong>2cureX<\/strong><\/p>\n\n\n\n<p><em><em><em>No news the past week<\/em><\/em><\/em><\/p>\n\n\n\n<p class=\"has-luminous-vivid-amber-color has-text-color has-medium-font-size\"><strong>SELECTED CASES<\/strong><\/p>\n\n\n\n<div class=\"wp-block-columns alignwide is-layout-flex wp-container-core-columns-is-layout-1 wp-block-columns-is-layout-flex\" style=\"margin-bottom:0\">\n<div class=\"wp-block-column has-luminous-dusk-gradient-background has-text-color has-background has-link-color wp-elements-5b03c1a033ae7b69f3a29f6f573cb4f5 is-layout-flow wp-block-column-is-layout-flow\" style=\"color:#000000;padding-top:2em;padding-right:2em;padding-bottom:2em;padding-left:2em\">\n<h2 class=\"wp-block-heading\" id=\"single\" style=\"font-size:25px\"><strong><a href=\"https:\/\/kapitalpartner.dk\/en\/biosergen\/\">Biosergen<\/a><\/strong><\/h2>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-css-opacity has-background is-style-wide\" style=\"background-color:#000000;color:#000000\"\/>\n\n\n\n<figure class=\"wp-block-image size-full\"><a href=\"https:\/\/kapitalpartner.dk\/en\/biosergen\/\"><img fetchpriority=\"high\" decoding=\"async\" width=\"868\" height=\"543\" src=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/04\/Biosergen-2-edited.jpg\" alt=\"\" class=\"wp-image-37787\" srcset=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/04\/Biosergen-2-edited.jpg 868w, https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/04\/Biosergen-2-edited-300x188.jpg 300w, https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/04\/Biosergen-2-edited-768x480.jpg 768w\" sizes=\"(max-width: 868px) 100vw, 868px\" \/><\/a><\/figure>\n\n\n\n<div class=\"wp-block-buttons alignfull is-horizontal is-content-justification-center is-layout-flex wp-container-core-buttons-is-layout-2 wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link\" href=\"https:\/\/kapitalpartner.dk\/en\/biosergen\/\">Investment case<\/a><\/div>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-column has-text-color has-background has-link-color wp-elements-db89c312aaa5ed4e502f64a296d400ef is-layout-flow wp-block-column-is-layout-flow\" style=\"background:linear-gradient(135deg,rgb(84,255,249) 0%,rgb(123,52,190) 89%);color:#000000;padding-top:2em;padding-right:2em;padding-bottom:2em;padding-left:2em\">\n<h2 class=\"wp-block-heading\" id=\"family\" style=\"font-size:25px\"><strong><a href=\"https:\/\/kapitalpartner.dk\/en\/curasight\/\">Curasight<\/a><\/strong><\/h2>\n\n\n\n<hr class=\"wp-block-separator has-css-opacity is-style-wide\"\/>\n\n\n\n<figure class=\"wp-block-image size-full\"><a href=\"https:\/\/kapitalpartner.dk\/en\/curasight\/\"><img decoding=\"async\" width=\"850\" height=\"532\" src=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/04\/Curasight-Ny-W-logo-1-edited.jpg\" alt=\"\" class=\"wp-image-37784\" srcset=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/04\/Curasight-Ny-W-logo-1-edited.jpg 850w, https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/04\/Curasight-Ny-W-logo-1-edited-300x188.jpg 300w, https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/04\/Curasight-Ny-W-logo-1-edited-768x481.jpg 768w\" sizes=\"(max-width: 850px) 100vw, 850px\" \/><\/a><\/figure>\n\n\n\n<div class=\"wp-block-buttons alignfull is-horizontal is-content-justification-center is-layout-flex wp-container-core-buttons-is-layout-3 wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link\" href=\"https:\/\/kapitalpartner.dk\/en\/curasight\/\">Investment Case<\/a><\/div>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-column has-text-color has-background has-link-color wp-elements-ea591003f737712a508b709da14cb93d is-layout-flow wp-block-column-is-layout-flow\" style=\"background:linear-gradient(135deg,rgb(202,248,128) 0%,rgb(46,174,63) 100%);color:#000000;padding-top:2em;padding-right:2em;padding-bottom:2em;padding-left:2em\">\n<h2 class=\"wp-block-heading\" id=\"patron\" style=\"font-size:25px\"><strong><a href=\"https:\/\/kapitalpartner.dk\/en\/positive-study-for-pain-patch-strengthens-cs-medicas-investment-case\/\">CS Medica<\/a><\/strong><\/h2>\n\n\n\n<hr class=\"wp-block-separator has-css-opacity is-style-wide\"\/>\n\n\n\n<figure class=\"wp-block-image size-full\"><a href=\"https:\/\/kapitalpartner.dk\/en\/positive-study-for-pain-patch-strengthens-cs-medicas-investment-case\/\"><img decoding=\"async\" width=\"1119\" height=\"701\" src=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/04\/CS-Medica-Screen-catch-1-1-edited.jpg\" alt=\"\" class=\"wp-image-37781\" srcset=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/04\/CS-Medica-Screen-catch-1-1-edited.jpg 1119w, https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/04\/CS-Medica-Screen-catch-1-1-edited-300x188.jpg 300w, https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/04\/CS-Medica-Screen-catch-1-1-edited-768x481.jpg 768w\" sizes=\"(max-width: 1119px) 100vw, 1119px\" \/><\/a><\/figure>\n\n\n\n<div class=\"wp-block-buttons alignfull is-horizontal is-content-justification-center is-layout-flex wp-container-core-buttons-is-layout-4 wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link\" href=\"https:\/\/kapitalpartner.dk\/en\/cs-medica-investment-case\/\">Investment case<\/a><\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n<p><\/p>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button has-custom-width wp-block-button__width-100 has-custom-font-size is-style-fill\" style=\"font-size:19px\"><a class=\"wp-block-button__link has-luminous-vivid-amber-to-luminous-vivid-orange-gradient-background has-background\" href=\"https:\/\/kapitalpartner.dk\/ugeafkast-paa-over-100-til-flere-aktier-mere-maaske-i-vente\/\">Interested in Nordic healthcare stocks? View our weekly Nordic newsletter here (in Danish)<\/a><\/div>\n<\/div>\n\n\n\n<p><\/p>\n\n\n\n<p class=\"has-luminous-vivid-amber-color has-text-color has-medium-font-size\"><strong>SHARE PRICE DEVELOPMENTS<\/strong><\/p>\n\n\n\n<p>On average, the Danish biotech stocks delivered a positive share price performance last week of 1.1%. In the past week, <strong>Saniona AB <\/strong>continued to reach new heights with a 40% increase, although the company did not report any company-specific news. <strong>CS Medica A\/S<\/strong> followed with a 11% increase after it got trademark approval in Canada. On the other hand, <strong>Expres2ion Biotech Holding AB<\/strong> fell after they announced 12-month durability data for ABNCoV2, a COVID-19 booster vaccine. <strong>Curasight A\/S, Zealand Pharma A\/S <\/strong>and <strong>Saniona AB<\/strong> have been the best performing stocks year-to-date after soaring 108-256% after among other things partnerships and positive recommendations from authorities paving the way for approvals. The Danish biotech stocks have done great year-to-date with a total return of 15.9%.<\/p>\n\n\n\n<p><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-vivid-red-color\"><strong>Read more about Curasight and Fluoguide:<\/strong><\/mark> <a href=\"https:\/\/kapitalpartner.dk\/en\/the-unique-cancer-treatment-of-the-future-todays-investment\/\">The unique cancer treatment of the future &#8211; Today&#8217;s investment<\/a><\/p>\n\n\n\n<p><strong>Overview of share price developments the past week, year-to-date and last twelve months<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"803\" height=\"637\" src=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/06\/image-24.png\" alt=\"\" class=\"wp-image-38592\" srcset=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/06\/image-24.png 803w, https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/06\/image-24-300x238.png 300w, https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/06\/image-24-768x609.png 768w\" sizes=\"(max-width: 803px) 100vw, 803px\" \/><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc. In the past week, several companies reported results from clinical trials including Ascendis Pharma, Expres2ion and IO Biotech. Further, Saniona continued to soar with [&hellip;]<\/p>\n","protected":false},"author":11,"featured_media":37397,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[9,29,165,205,163,113],"tags":[],"class_list":["post-38630","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-en-investeringscases","category-investeringscases","category-investment-cases","category-news","category-sector-cases","category-sektorcases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Danish Biotech Weekly - Week 25 | Kapital Partner A\/S<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-25\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Danish Biotech Weekly - Week 25 | Kapital Partner A\/S\" \/>\n<meta property=\"og:description\" content=\"Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc. In the past week, several companies reported results from clinical trials including Ascendis Pharma, Expres2ion and IO Biotech. Further, Saniona continued to soar with [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-25\/\" \/>\n<meta property=\"og:site_name\" content=\"Kapital Partner A\/S\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/kapitalpartner\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-19T08:31:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-19T08:31:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1015\" \/>\n\t<meta property=\"og:image:height\" content=\"533\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Anders S\u00f8ndergaard\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@KapitalPartner\" \/>\n<meta name=\"twitter:site\" content=\"@KapitalPartner\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Anders S\u00f8ndergaard\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-25\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-25\/\"},\"author\":{\"name\":\"Anders S\u00f8ndergaard\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed\"},\"headline\":\"Danish Biotech Weekly &#8211; Week 25\",\"datePublished\":\"2023-06-19T08:31:52+00:00\",\"dateModified\":\"2023-06-19T08:31:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-25\/\"},\"wordCount\":524,\"publisher\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-25\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png\",\"articleSection\":[\"All investment Cases\",\"Investeringscases\",\"Investment cases\",\"News\",\"Sector cases\",\"Sektorcases\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-25\/\",\"url\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-25\/\",\"name\":\"Danish Biotech Weekly - Week 25 | Kapital Partner A\/S\",\"isPartOf\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-25\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-25\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png\",\"datePublished\":\"2023-06-19T08:31:52+00:00\",\"dateModified\":\"2023-06-19T08:31:55+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-25\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-25\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-25\/#primaryimage\",\"url\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png\",\"contentUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png\",\"width\":1015,\"height\":533},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-25\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/kapitalpartner.dk\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Investment cases\",\"item\":\"https:\/\/kapitalpartner.dk\/en\/category\/investment-cases\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Sector cases\",\"item\":\"https:\/\/kapitalpartner.dk\/en\/category\/investment-cases\/sector-cases\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Danish Biotech Weekly &#8211; Week 25\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/kapitalpartner.dk\/#website\",\"url\":\"https:\/\/kapitalpartner.dk\/\",\"name\":\"Kapital Partner A\/S\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/kapitalpartner.dk\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\",\"name\":\"Kapital Partner A\/S\",\"url\":\"https:\/\/kapitalpartner.dk\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png\",\"contentUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png\",\"width\":496,\"height\":432,\"caption\":\"Kapital Partner A\/S\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/kapitalpartner\",\"https:\/\/x.com\/KapitalPartner\",\"https:\/\/www.linkedin.com\/company\/10438322\",\"https:\/\/www.youtube.com\/channel\/UCODuY5PE_fxmp2nSSsq3l3w\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed\",\"name\":\"Anders S\u00f8ndergaard\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g\",\"caption\":\"Anders S\u00f8ndergaard\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Danish Biotech Weekly - Week 25 | Kapital Partner A\/S","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-25\/","og_locale":"en_US","og_type":"article","og_title":"Danish Biotech Weekly - Week 25 | Kapital Partner A\/S","og_description":"Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc. In the past week, several companies reported results from clinical trials including Ascendis Pharma, Expres2ion and IO Biotech. Further, Saniona continued to soar with [&hellip;]","og_url":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-25\/","og_site_name":"Kapital Partner A\/S","article_publisher":"https:\/\/www.facebook.com\/kapitalpartner","article_published_time":"2023-06-19T08:31:52+00:00","article_modified_time":"2023-06-19T08:31:55+00:00","og_image":[{"width":1015,"height":533,"url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png","type":"image\/png"}],"author":"Anders S\u00f8ndergaard","twitter_card":"summary_large_image","twitter_creator":"@KapitalPartner","twitter_site":"@KapitalPartner","twitter_misc":{"Written by":"Anders S\u00f8ndergaard","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-25\/#article","isPartOf":{"@id":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-25\/"},"author":{"name":"Anders S\u00f8ndergaard","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed"},"headline":"Danish Biotech Weekly &#8211; Week 25","datePublished":"2023-06-19T08:31:52+00:00","dateModified":"2023-06-19T08:31:55+00:00","mainEntityOfPage":{"@id":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-25\/"},"wordCount":524,"publisher":{"@id":"https:\/\/kapitalpartner.dk\/#organization"},"image":{"@id":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-25\/#primaryimage"},"thumbnailUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png","articleSection":["All investment Cases","Investeringscases","Investment cases","News","Sector cases","Sektorcases"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-25\/","url":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-25\/","name":"Danish Biotech Weekly - Week 25 | Kapital Partner A\/S","isPartOf":{"@id":"https:\/\/kapitalpartner.dk\/#website"},"primaryImageOfPage":{"@id":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-25\/#primaryimage"},"image":{"@id":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-25\/#primaryimage"},"thumbnailUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png","datePublished":"2023-06-19T08:31:52+00:00","dateModified":"2023-06-19T08:31:55+00:00","breadcrumb":{"@id":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-25\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-25\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-25\/#primaryimage","url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png","contentUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png","width":1015,"height":533},{"@type":"BreadcrumbList","@id":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-25\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/kapitalpartner.dk\/en\/"},{"@type":"ListItem","position":2,"name":"Investment cases","item":"https:\/\/kapitalpartner.dk\/en\/category\/investment-cases\/"},{"@type":"ListItem","position":3,"name":"Sector cases","item":"https:\/\/kapitalpartner.dk\/en\/category\/investment-cases\/sector-cases\/"},{"@type":"ListItem","position":4,"name":"Danish Biotech Weekly &#8211; Week 25"}]},{"@type":"WebSite","@id":"https:\/\/kapitalpartner.dk\/#website","url":"https:\/\/kapitalpartner.dk\/","name":"Kapital Partner A\/S","description":"","publisher":{"@id":"https:\/\/kapitalpartner.dk\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/kapitalpartner.dk\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/kapitalpartner.dk\/#organization","name":"Kapital Partner A\/S","url":"https:\/\/kapitalpartner.dk\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/","url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png","contentUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png","width":496,"height":432,"caption":"Kapital Partner A\/S"},"image":{"@id":"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/kapitalpartner","https:\/\/x.com\/KapitalPartner","https:\/\/www.linkedin.com\/company\/10438322","https:\/\/www.youtube.com\/channel\/UCODuY5PE_fxmp2nSSsq3l3w"]},{"@type":"Person","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed","name":"Anders S\u00f8ndergaard","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g","caption":"Anders S\u00f8ndergaard"}}]}},"_links":{"self":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/38630"}],"collection":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/comments?post=38630"}],"version-history":[{"count":1,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/38630\/revisions"}],"predecessor-version":[{"id":38631,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/38630\/revisions\/38631"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/media\/37397"}],"wp:attachment":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/media?parent=38630"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/categories?post=38630"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/tags?post=38630"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}